Specialists Rethink Lung Cancer Treatment Plans, With Eye On IO Biomarkers
Plenary speaker at this year's ASCO meeting, Leena Gandhi, envisioned a future where individual patients receive a precisely defined immunotherapy regimen.
You may also be interested in...
The recently launched Opdivo/Yervoy combination already has a leading position in first-line kidney cancer in the US – with a 30% share of new patients – but has been rejected in Europe.
Over two days, stakeholders will get a complete picture of the checkpoint inhibitor market as the four major immuno-oncology sponsors report second quarter sales and earnings.
With the FDA updating its stance on interchangeability, analysts will be pushing Amgen and AbbVie on how the policy changes will affect biosimilar competition. Celgene and Allergan will be under pressure for R&D updates; Allergan remains in the hot seat on its pipeline growth strategy from activist investors.